To give accurate information is our responsibly.
What if CAR-T therapy no longer required collecting a patient’s immune cells, sending them to a specialized manufacturing facility, genetically engineering them, expanding them, testing …
Gene therapy in 2026 is entering a more commercially important phase. The industry is no longer asking whether genetic diseases can be treated by modifying …
BioNTech’s decision to terminate its Phase 2 colorectal cancer vaccine trial is an important warning for the mRNA oncology industry: promising technology alone does not …
The obesity drug market is entering a new competitive phase. The first question was whether GLP-1 therapies could transform obesity treatment. They already have. Sample …
mRNA has already changed vaccine development. The bigger question now is: Can mRNA become a scalable platform for personalized cancer treatment? The answer in 2026 …
The next battle in obesity treatment is no longer simply GLP-1 vs. GLP-1. Between 2026 and 2030, competition is likely to be defined by a …
Saudi Arabia’s biotechnology opportunity is no longer simply about selling innovative medicines into a growing healthcare system. The bigger opportunity is being created around local …
Eli Lilly’s Mounjaro (tirzepatide) has moved beyond its established role in blood-glucose management. On August 28, 2026, the U.S. Food and Drug Administration (FDA) expanded …
2026 is emerging as another important year for pharmaceutical innovation, with new therapies addressing obesity, cardiovascular disease, rare neurological disorders, cancer, infectious diseases, kidney disease …
FDA Drug Approvals 2026: Innovation Is Moving From Blockbusters to Precision Medicine, Oral Therapies and Rare Diseases The U.S. pharmaceutical industry has entered another important …
by